Frontiers in Science & Technology: Using Stem Cells to Cure Diabetes
Category:Frontiers in Science & Technology
12:00 PM to 1:30 PM
CONNECT Frontiers in Science and Technology
In partnership with Morrison & Foerster LLP
presents
Using Stem Cells to Cure Diabetes
Presented by:
E. Edward Baetge, Ph.D.
Senior Vice President & Chief Scientific Officer
Novocell
Program Overview:
Type 1 Diabetes, also known as juvenile-onset diabetes, affects nearly 3 million Americans, with more than 15,000 children being diagnosed each year. It is the single most costly chronic disease, and in 2007, accounted for $174 billion in health-care costs in the U.S. There is no cure for Type 1 Diabetes, and for decades researchers have been searching for ways to replace the insulin-producing cells of the pancreas that are destroyed by a patient's own faulty immune system.
Recent breakthroughs in this field have led Dr. Baetge, and his team at Novocell, to develop and patent an innovative stem cell therapy to produce functional pancreatic, insulin-producing cells using human embryonic stem cells. This therapy is being designed to be injected into the bodies of diabetics to replace cells that no longer produce insulin. He feels their methods of employing stem cells as a renewable source of cell replacement therapy could lead to the first widespread treatment for diabetes. In addition, his team has published very favorable results using this therapy, where they were able to stop diabetes when the cells were implanted in mice.
However, the development of a replacement cell therapy product will entail more than just a renewable pancreatic cell source. Both the scale up and delivery of this product will require critical elements, and the incorporation of these additional elements will provide the basis to conduct clinical trials in patients with diabetes.
** October 28, 2009 - Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes **
Who Should Attend:
Scientists, engineers, physicians, healthcare leaders, venture capitalists, technology and life sciences professionals, services providers, and business leaders.
About the Presenter:
E. Edward Baetge, Ph.D., is currently Senior Vice President and Chief Scientific Officer of Novocell formed by the merger of CyThera and BresaGen Inc. in 2004. He was recruited to CyThera as Chief Scientific Officer in 2001 to head its then emerging human embryonic stem cell program. Prior to joining CyThera, Dr. Baetge held the position of Chief Scientific Officer at Modex Therapeutics Ltd from 1997-2001., in Lausanne, Switzerland, which developed one of the first autologous adult stem cell products for the treatment of chronic skin ulcers. Before Modex, Dr. Baetge held management positions at CytoTherapeutics from 1992-1997 and at Bristol-Myers Squibb from 1987-1992 . He holds a Ph.D. in molecular neurobiology from Cornell University and completed postdoctoral work at Cornell University and the Howard Hughes Medical Institute. Dr. Baetge has published extensively in the field of cell therapy and has produced a number of cell technology patents.
Event details:
Date: November 17, 2009
Time: 12:00 noon – 1:30 p.m.
Location: AMN Healthcare
12400 High Bluff Drive # 100
San Diego, CA 92130
Note: Lunch will be provided for participants.
Contact: Bethany Kraynack
Email: bkraynack@connect.org
Phone: 858-964-1312
Fees: CONNECT Members: $15
Non-Members: $25
Students: $10
At the Door $35
Pre-Registration for this meeting is now CLOSED. On-Site regsitration will be available for $35.
With billions of stimulus funding, the US government is encouraging national adoption of Electronic Health Record (EHR) systems. At least $19B will be going into payment to providers for adopting “meaningful use” of “interoperable Electronic health record (EHR) technology.” More is being directed into “Health Information Exchanges” to provide a means for EHRs to communicate. Through all this government spending, an infrastructure for storing and transmitting digital medical data will be created.
At the same time, entrepreneurs are developing amazingly accurate new medical sensor and diagnostic technologies that collect and communicate significant amounts of data. But how will that data be accessed by medical providers, and how should it be incorporated into the EHR infrastructure?
In addition, according to a report done by PricewaterhouseCoopers (PWC) Health Industries Group, 76% of the more than 700 healthcare executives surveyed in June 2009 said that the information gathered in EHRs will be their organization's biggest asset in the next five years. But very few healthcare organizations are building systems and care delivery processes to effectively use the billions of gigabytes of data being collected.
Where are the most attractive opportunities for entrepreneurial businesses in this dynamic market? How can entrepreneurs create value with the explosion of technologies for medical information and the evolving generation, management, and use of electronic medical data?
SPEAKERS
Mike Murphy - CEO, Sharp HealthCare
Michael Doyle - CEO, Medsphere Systems Corp.
Vic Kheterpal, M.D. - CEO, Care Evolution
Charles Gropper - Vice President, R&D, CardioNet
Timothy Wollaeger - Managing Director, Sanderling Ventures